Secondary Logo

Journal Logo

October 1999 - Volume 22 - Issue 5
pp: 429-533

‘Neo-FAC’ (5-Fluorouracil, Doxorubicin, and Cyclophosphamide) for Poor-Prognosis Stage IV Breast Cancer: A Southwest Oncology Group Phase II Study

Ellis, Georgiana K.; Green, Stephanie; Livingston, Robert B.; More

American Journal of Clinical Oncology. 22(5):446, October 1999.

Phase II Trial of a Novel Platinum Analog, SKI 2053R, in Patients With Previously Untreated Extensive-Stage Small-Cell Lung Cancer

Zang, Dae Young; Lee, Kyoo Hyung; Lee, Jung Shin; More

American Journal of Clinical Oncology. 22(5):495, October 1999.

North Central Cancer Treatment Group Phase II Study of 5-Fluorouracil and High-Dose Levamisole for Gastric and Gastroesophageal Cancer Using Survival as the Primary Endpoint of Efficacy

Burch, Patrick A.; Keppen, Michael D.; Schroeder, Georgene; More

American Journal of Clinical Oncology. 22(5):505, October 1999.

Paclitaxel and G-CSF in Previously Untreated Patients With Extensive Stage Small-Cell Lung Cancer: A Phase II Study of the North Central Cancer Treatment Group

Kirschling, Ron J.; Grill, Joseph P.; Marks, Randolph S.; More

American Journal of Clinical Oncology. 22(5):517, October 1999.

Large Proportion of Epstein-Barr Virus–Associated Small Noncleaved Cell Lymphomas Among Children With Non-Hodgkin’s Lymphoma at a Single Institution in Moscow, Russia

Sandlund, J. T.; Gorban, Z. I.; Berard, C. W.; More

American Journal of Clinical Oncology. 22(5):523, October 1999.


From M. D. Anderson Cancer Center



Show: